Journal of Pharmaceutical and Biomedical Analysis 50 (2009) 96–99

Contents lists available at ScienceDirect

Journal of Pharmaceutical and Biomedical Analysis

journal homepage: www.elsevier.com/locate/jpba

Short communication

A direct HPLC method for the resolution and quantitation of the R-(−)- and S-(+)-enantiomers of vigabatrin (γ-vinyl-GABA) in pharmaceutical dosage forms using teicoplanin aglycone chiral stationary phase

Abdulrahman A. Al-Majed*

Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

ARTICLE INFO

Article history:
Received 3 December 2008
Received in revised form 23 March 2009
Accepted 25 March 2009
Available online 5 April 2009

Keywords:
Vigabatrin enantiomers
Teicoplanin aglycone chiral stationary phase
Pharmaceutical products
HPLC
UV detection

ABSTRACT

A direct chiral high-performance liquid chromatography (HPLC) method was developed and validated for the resolution and quantification of antiepileptic drug enantiomers, R-(−)- and S-(+)-vigabatrin (gamma-vinyl-gamma-aminobutyric acid) in pharmaceutical products. The separation was optimized on a macrocyclic glycopeptide antibiotic chiral stationary phase (CSP) based on teicoplanin aglycone, chirobiotic (TAG), using a mobile phase system containing ethanol–water (80:20, v/v), at a flow rate of 0.4 ml/min and UV detection set at 210 nm. The stability of vigabatrin enantiomers under different degrees of temperature was also studied. The enantiomers of vigabatrin were separated from each other. The calibration curves were linear over a range of 100–1600 μg/ml ($r = 0.999$) for both enantiomers. The overall recoveries of R-(−)- and S-(+)-vigabatrin enantiomers from pharmaceutical products were in the range of 98.3–99.8% with %RSD ranged from 0.48 to 0.52%. The limit of quantification (LOQ) and limit of detection (LOD) for each enantiomer were 100 and 25 μg/ml, respectively. No interferences were found from commonly co-formulated excipients.

1. Introduction

Increasing demands for the separation of chiral compounds, and production of enantiomerically pure compounds have led to enantioselective separation becoming one of the most important analytical task [1]. Over the past few years, it has been demonstrated that the chiral stationary phases (CSPs) based on macrocyclic antibiotics (teicoplanin, teicoplanin aglycone, vancomycin, ristotecin A, etc.) are extremely useful for enantiometric separations of racemic compounds and appear particularly suitable for preparative chromatography [2–4]. One of the recent selectors is teicoplanin. The aglycone-derivative of teicoplanin appears to be especially suited for the separation of underivatized amino acids [5]. Teicoplanin aglycone TAG differs from teicoplanin by the lack of the sugar chains.

Vigabatrin (γ-vinyl-γ-aminobutyric acid, γ-vinyl-GABA) is one of the newer generation of antiepileptic drugs. It is a structural analogue of γ-aminobutyric acid (GABA) (Fig. 1). It acts by irreversibly inhibiting the enzyme GABA transaminase in brain, increasing GABA concentrations and reducing seizure activity [6]. Nowadays, vigabatrin is regarded by many authorities as a drug of choice in infants with West syndrome (infantile spasms), particularly in cases associated with tuberous sclerosis [7,8]. Vigabatrin is supplied as a racemic mixture of the enantiomers, but only the (S)-(+)-enantiomer is pharmacologically active [9]. Therefore it is useful to provide chiral separation and enantiometric analysis methods of this drug.

In the past decade, several analytical methods, such as high-performance liquid chromatography (HPLC) method [10–12] and capillary electrophoresis (CE) method [13,14] for the determination of vigabatrin have been developed. However, only few methods have been described to date for the chiral separation of vigabatrin enantiomers. Haegele et al. [15] reported a gas chromatography–mass spectrometry (GC–MS) method for the determination of vigabatrin enantiomers. Schramm et al. [16] developed a gas–liquid chromatography (GLC) method to detect the content of vigabatrin enantiomers in plasma or serum. Although GC methods are relatively sensitive, they require complex sample preparation involving double derivatization of the drugs to improve the volatility and avoid column interactions. An HPLC method with pre-column derivatization has also been presented for the analysis of vigabatrin enantiomers [17,18]. But the method of derivatization may often be time-consuming, frequently requires strict control to temperature and rigorous sample clean up or undergo cross-reaction during the analysis. The direct resolution of racemic vigabatrin by HPLC without derivatization is very rare. Recently, Lee et al. attempted to resolve racemic vigabatrin and its analogue γ-amino acids on liquid chromatographic chiral stationary phases

* Tel.: +966 1 467 7464; fax: +966 1 467 6220.
E-mail address: almajed99@yahoo.com.

0731-7085/$ – see front matter © 2009 Published by Elsevier B.V.
doi:10.1016/j.jpba.2009.03.030



Fig. 1. The chemical structure of (A) S-(+)-vigabatrin, (B) R-(−)-vigabatrin, and (C) GABA.

(CSPS) based on (+)-(18-crwon-6)-2,3,11,12-tetracarboxylic acid [19], but this method was only dealing with resolution of vigabatrin enantiomers and its analogue and was not applied for the analysis of the drug in its pharmaceutical dosage forms.

The aim of this work was to develop and validate a simple stereoselective HPLC method with UV detection based on the use of a teicoplanin aglycone macrocyclic antibiotic CSP for the direct enantioselective analysis of vigabatrin in pharmaceutical formulations. With the present broad range of available CSPs and advances in column technology, the present enantioselective HPLC can be considered as the method of choice for the quantitation of racemic vigabatrin without previous derivatization.

2. Experimental

2.1. Chemical and reagents

(±)-vigabatrin, S-(+)-vigabatrin and R-(−)-vigabatrin were purchased from Sigma Chemical Co. (St Louis, MO, USA). Ethanol as HPLC-grade was purchased from BDH Chemicals (Poole, UK). Water was deionized and doubly distilled using a cartridge system (Picotech water system, RTP, NC, USA). Sabril tablets (containing 500 mg of vigabatrin as racemate/tablet) were purchased from the local market.

2.2. Instrumentation and chromatographic conditions

The resolution of the enantiomers was performed on a Waters Breeze system consisting of a 1525 Binary HPLC pump, 717 plus autosampler, 2487 Dual channel absorbance detector and In-line degasser AF (Milford, MA, USA). The column used for the analytical separation was the macrolide-type antibiotic teicoplanin aglycone known as chirobiotic TAG (15 cm × 4.6 mm i.d., 5 μm particle size) purchased from Advanced Separation Technologies (Whippany, NJ, USA).

The mobile phase consisted of ethanol:water (80:20, v/v) and was filtered through a Millipore membrane filter (0.2 μm) from Nihon, Millipore (Yonezawa, Japan). The flow rate was 0.4 ml/min, the sample injection volume was 20 μL.

The appropriate wavelength for the detection of the drug was determined by wavelength scanning over the range of 200–400 nm with a Shimadzu UV-double beam spectrometer and the chromatograms were monitored by UV detection at a wavelength of 210 nm.

2.3. Preparation of standard stock solutions

Stock solutions of S-(+)-vigabatrin, R-(−)-vigabatrin (2.0 mg/ml) were prepared by dissolving the appropriate amount of substances in water. A seven-point non-zero calibration standard curve, ranging from 100 to 1600 μg/ml, was prepared.

2.4. Preparation of standard solutions of tablets

An accurately weighed amount equivalent to 50 mg vigabatrin was transferred into 100 ml volumetric flask with the aid of 50 ml of water and stirred for 10 min. The extract was filtered and complete to volume with water. Accurately measured aliquots of the supernatant were transferred to 5 ml volumetric flasks diluted to 5 ml with water to give final concentration of 250, 750 and 1600 μg/ml of vigabatrin.

3. Results and discussion

3.1. Optimization of the chromatographic conditions

In order to get optimum resolution and selectivity for the two enantiomers from pharmaceutical preparations, various macrocyclic antibiotic CSPs and various experiments were conducted. The chiral separation was optimized using isocratic conditions as these offer more rapid analysis attributable to the presence of column re-equilibration steps.

The separation of vigabatrin enantiomers was first attempted using vancomycin CSP, teicoplanin CSP and ristotecin. However, despite the use of a range of different possible mobile phase compositions, no separation was achieved for vigabatrin enantiomers on any of the three columns (data not shown). In order to improve the resolution of vigabatrin enantiomers, teicoplanin aglycone chiral stationary phase (TAG CSP) was used.

Several mobile phase compositions were tested on teicoplanin TAG CSP. With the mobile phase consisted of methanol or ethanol, no enantioseparation was observed in the absence of water. While with methanol in the presence of water, separation was poor, with ethanol, the enantioresolution increased with increasing water concentration in the mobile phase. An increase of water concentration in ethanol in the mobile phase to about 15%, partial enantioseparation of the studied enantiomers were obtained (Rs = 1.1). Increasing the concentration of water with ethanol to about 20%, a significant improvement in both the resolution and sensitivity was achieved (Rs = 2.91). The increase in resolution with increasing water content was due to enhanced hydrophobic interactions in the water-rich mobile phase, while the increase in the resolution with increasing ethanol content was due to the decreased solubility of polar vigabatrin in ethanol-rich mobile phase [20].

It was also found that no significant influence of the pH in the range of 5–7 was observed on retention or separation. This can be easily explained by the fact that the vigabatrin molecule is present in its zwitterionic form at this pH range (carboxylic moiety pKa ∼4.0, amine moiety 8.6) and the function groups of the tiecoplanin-aglycone molecule involved in the chiral discrimination also have their pKa values (acidic group ∼4.0, basic group ∼9.2 [5]) far from this pH change.

From this study, the optimized conditions of ethanol–water (80:20, v/v) (Table 1) were established as the final mobile phase conditions with TAG CSP at flow rate 0.4 ml/min. This simple mobile phase is advantageous particularly if method is transferred to

Table 1
Validation parameters for the determination of vigabatrin enantiomers using the proposed method.

Parameter	S-(+)-vigabatrin	R-(−)-vigabatrin
Intercept (a)	0.019	0.018
Slope (b)	0.006	0.004
Correlation coefficient (r)	0.999	0.999
$S_{y/x}$	0.031	0.026
S_a	0.033	0.028
S_b	0.0002	0.0001
LOQ (μg/ml)	100	100
LOD (μg/ml)[a]	25	25

[a] S/N = 3.

preparative scale since the separated analytes can easily be isolated by evaporating the solvent.

Typical chromatograms for the chiral separation of vigabatrin enantiomers are presented in Fig. 2. Under the above optimizing conditions, S-(+)-vigabatrin (7.94 min) was eluted before R-(−)-vigabatrin (9.85 min), since the R-(−)-enantiomer interacts with the chiral selector more strongly. Elution order was verified by running the chromatograms of the optically pure enantiomers of the studied drug under identical HPLC conditions.

3.2. Mechanism of retention and separation

From the aspect of enantiometric separation, several suggestions regarding the mechanism of retention and separation can be reached. The studied enantiomers of vigabatrin (Fig. 1) contain nitrogen and oxygen atoms, which interact with the complimentary groups on the chiral selector. In the case in which the process takes place in a basket-like cavity on teicoplanin TAG CSP [21], it is the "ability" of one enantiomer (with respect to the other) to reach a better steric fit in the cavity that induces the separation.

Through hindrance effect, a carbonate moiety present on teicoplanin aglycone may have an important role in the separation of vigabatrin enantiomers, as they block possible interaction sites on the aglycone itself, and offer competing interaction sites. This is particularly important for γ-aminobutyric acids, which are thought to "dock" and bind inside the cleft of the aglycone near its amino function groups. Obviously, the lack of the sugar moiety allows a stronger docking of the vigabatrin enantiomers with less steric hindrance [21,22].

The combination of hydrogen-bond, dipole–dipole and short-distance Van der Waals interactions may to varying degrees favor the stabilization of the enantiomer–CSP complexes. Obviously, these effects strictly depend how the enantiomers fit the aglycone cavity [20].



Fig. 2. Chromatogram of [I] S-(+)-vigabatrin, 1200 μg/ml and [II] R-(−)-vigabatrin, 1200 μg/ml, recovered from Sabril tablet.

From the results relating to the possible chiral recognition mechanism, it can be concluded that there is no valid conception for the chiral recognition of racemic vigabatrin on macrocyclic glycopeptides-based CSPs including teicoplanin aglycone. There are probably several suggestions, but further efforts should be made to clarify the real mechanism, which can facilitate the optimization of the separations of the drugs on teicoplanin aglycone CSP.

3.3. Method validation

From the preliminary trials to optimize the conditions for S-(+)- and R-(−)-vigabatrin separation upon a chirobiotic TAG column, it was found that the mobile phase composed of ethanol–water (80:20, v/v), a flow rate of 0.4 ml/min at 25° gave the best enantioselectivity and enantioseparation values with suitable short retention times. Therefore under these optimal conditions, the method was applied to the enantioselective analysis of the drug enantiomers in pharmaceutical formulations and validated according to ICH [23].

3.3.1. Linearity

Under the optimized working conditions, standard calibration curves for each enantiomer were linear over the concentration range of 100–1600 μg/ml, with the linear regression equation $y = 0.019 + 0.006x$ for S-(+)-vigabatrin and $y = 0.018 + 0.004x$ for R-(−)-vigabatrin and correlation coefficient (r) of 0.999 for both enantiomers. These concentration ranges resulted were suitable to test the linearity at the levels normally observed for vigabatrin in its pharmaceutical formulations.

3.3.2. Limit of detection (LOD), limit of quantitation (LOQ) and accuracy

The lowest LOD and the LOQ were determined based on signal-to-noise ratios using analytical responses of 3 and 10 times the background noise, respectively [24]. The LOD and the LOQ for each enantiomers were calculated to be 25 and 100 μg/ml, respectively. The results of the statistical analysis of the experimental data, such as the slopes, the intercepts and the correlation coefficients obtained by the least squares treatment of the results along with standard deviation of the slopes and intercepts on the ordinate and the standard deviation of the residuals were shown in Table 1. The accuracy of the method was tested by analyzing different concentrations of standard vigabatrin enantiomers. The overall recoveries of vigabatrin enantiomers by the proposed method were 98.5 and 98.7% for S-(+)- and R-(−)-vigabatrin, respectively, with %RSD of 0.85 and 0.87 for S-(+)- and R-(−)-vigabatrin, respectively. In both cases, the results are satisfactorily low and hence the method is sufficiently accurate and precise.

3.3.3. Application to pharmaceutical products

The validity of the method developed was further applied to various concentrations taken from the pharmaceutical commercial formulations (Sabril tablets) for determining their content of vigabatrin enantiomers. The values of the overall drug percentage recoveries of S-(+)- and R-(−)-vigabatrin were 98.9 with %RSD of 0.48 and 99.3% with %RSD of 0.52, respectively. The results indicate that this proposed method can determine the enantiomers of vigabatrin in the drug product accurately and precisely.

3.3.4. Specificity

Excipients commonly co-formulated with the studied drug such as magnesium stearate, cellulose, starch, calcium hydrogen phosphate, colloidal silicon dioxide and coloring agents, also did not interfere with the determination of vigabatrin enantiomers, indicated a high degree of specificity of the method for the drug in its pharmaceutical dosage forms.

3.3.5. Robustness

The optimum HPLC conditions of vigabatrin enantiomers were used to evaluate the method robustness under modified conditions. The small changes made include the flow rate, detection wavelength, time (day) and temperature (±10%). It was found that the percent recoveries of vigabatrin enantiomers were good under most conditions and remain unaffected by small changes of experimental parameters but deliberate, demonstrating sufficient robustness.

4. Conclusion

An enantioselective HPLC method that enables sensitive determination of S-(+)- and R-(−)-vigabatrin in pharmaceutical products was developed. The method is selective where excipients commonly co-formulated with the studied drug do not interfere. The proposed method is considered as the first method proved to be capable to direct separate γ-amino acid (vigabatrin) by utilizing teicoplanin aglycone CSP without derivatization. Moreover, the UV detectors coupled to HPLC are widely available in many analytical laboratories, and this assures the broadest applicability to the method. Also this method can be used as chiral quality control for vigabatrin formulations by HPLC.

Acknowledgments

The author wishes to gratefully acknowledge helpful suggestions from Dr. M. Hefnawy. The author also would like to thank Mr. T. Butt for the help in editing the manuscript.

References

[1] T.E. Beesley, R.P. Scott, Chiral Chromatography, John Wiley & Sons, Ltd., 1998, pp. 23–26.
[2] D.W. Armstrong, Y.B. Tang, S.S. Chen, Y.W. Zhou, C. Bagwill, J.R. Chen, Anal. Chem. 66 (1994) 1473–1484.
[3] D.W. Armstrong, K.L. Rundlett, J.R. Chen, Chirality 6 (1994) 496–509.
[4] H. Jiang, Y. Li, M. Pelzer, M. Canon, C. Randlett, J. Chromatogr. A 1192 (2008) 230–238.
[5] A. Berthod, X.H. Chen, J.P. Kullman, D.W. Armstrong, F. Gasparrini, I. D'Acquarica, C. Villani, A. Carotti, Anal. Chem. 72 (2000) 1767–1780.
[6] W.C. Walker, P.N. Patsalos, Pharmacol. Ther. 67 (1995) 351–384.
[7] R. Riikonen, Curr. Opin. Neurol. 18 (2005) 91–95.
[8] P. Curatolo, R. Bombardieri, C. Cerminara, Curr. Opin. Neurol. 19 (2006) 119–131.
[9] B.S. Meldrum, K. Murugaiah, Eur. J. Pharmacol. 89 (1983) 149–152.
[10] T.A.C. Vermeij, P.M. Edelbroek, J. Chromatogr. B 810 (2004) 297–303.
[11] N. Wad, G. Kramer, J. Chromatogr. B 705 (1998) 154–158.
[12] S.M. Cetin, S. Atmaca, J. Chromatogr. A 1031 (2004) 237–242.
[13] N. Benturquia, S. Parrot, V. SaUVinet, B. renaud, L. Denoroy, J. Chromatogr. B 806 (2004) 237–244.
[14] S.Y. Chang, W.-C. Lin, J. Chromatogr. B 794 (2003) 17–22.
[15] K.D. Haegele, J. Schoun, R.G. Alken, N.D. Huebert, J. Chromatogr. 274 (1983) 103–110.
[16] T.M. Schramm, G.E. McKinnon, M.J. Eadie, J. Chromatogr. Biomed. Appl. 616 (1993) 39–44.
[17] V. Franco, I. Mazzucchelli, C. Fattore, R. Marchiselli, G. Gatti, E. Perucca, J. Chromatogr. B 854 (2007) 63–67.
[18] C.-Y. Hsieh, S.-Y. Wang, A.-L. Kwan, H.-L. Wu, J. Chromatogr. A 1178 (2008) 166–170.
[19] S.J. Lee, H.S. Cho, H.J. Choi, M.H. Hyun, J. Chromatogr. A 1188 (2008) 318–321.
[20] A. Peter, R. Torok, D.W. Armstrong, J. Chromatogr. A 1057 (2004) 229–235.
[21] A. Cvazzini, G. Nadalini, F. Dondi, F. Gasparrini, A. Ciogli, C. Villani, J. Chromatogr. A 1031 (2004) 143–158.
[22] D.H. Williams, B. Bardsley, Angew. Chem. Int. Ed. Engl. 38 (1999) 1172–1193.
[23] International conference on harmonization (ICH) guidelines (2005), Validation of analytical procedures—text and methodology Q2 (R1).
[24] The United State Pharmacopeia, 24th ed., United State Pharmacopeial Convention, Rockville, MD, 2000, p. 2150.